ankyrin repeat domain 20 family member A6, pseudogeneGenealiases: []
Q-omics provides the consensus-scored ANKRD20A6P profile across patient tissues and cancer cell-line models. ANKRD20A6P expression is associated with patient survival in 6 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, ANKRD20A6P is differentially expressed in 3, with the highest sampling consensus in THCA. Additionally, ANKRD20A6P RNA expression shows 5,990 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight KIRC, THCA, and TGCT as cancer lineages where ANKRD20A6P shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ANKRD20A6P — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ANKRD20A6P survival associations across molecular data types. ANKRD20A6P RNA expression shows survival associations in the most cancer types (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ANKRD20A6P RNA expression–survival associations across cancer types. High ANKRD20A6P expression shows unfavorable associations in KIRC, KIRP, LIHC, STAD, SARC and BRCA. The KIRC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .010). Together, the overview and detailed table identify KIRC as the clearest survival context for ANKRD20A6P RNA expression.
This table summarizes ANKRD20A6P tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 3. The strongest signals are observed in THCA for RNA.
This table ranks reproducible tumor–normal expression differences for ANKRD20A6P. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ANKRD20A6P shows lower tumor expression in THCA and higher tumor expression in KIRC and LIHC. The THCA box plot shows higher ANKRD20A6P RNA expression in normal versus tumor tissue (log2 FC = −0.150, t-test p = .023).
This table shows molecular features associated with ANKRD20A6P in patient tissues and cancer cell lines. In patient samples, ANKRD20A6P shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set.
